Anti-topoisomerase I autoantibodies in systemic sclerosis

被引：34

作者：

Czoempoely, Tamas

Simon, Diana ^{[2
]}

Czirjak, Laszlo ^{[2
]}

Peter Nemeth ^{[1
]}

机构：

[1] Univ Pecs, Fac Med, Dept Immunol & Biotechnol, H-7643 Pecs, Hungary

[2] Univ Pecs, Dept Immunol & Rheumatol, H-7632 Pecs, Hungary

来源：

AUTOIMMUNITY REVIEWS | 2009年 / 8卷 / 08期

基金：

匈牙利科学研究基金会;

关键词：

Systemic sclerosis; Autoantibodies; Anti-topoisomerase I; Epitope mapping; SCLERODERMA PATIENTS; STIMULATORY AUTOANTIBODIES; PDGF RECEPTOR; DNA; ANTIBODIES; SCL-70; ANTICENTROMERE; EPITOPES; DISEASE; SERA;

D O I：

10.1016/j.autrev.2009.02.018

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Systemic sclerosis (SSc) is an autoimmune disease characterized by fibrosis of the skin, vascular abnormalities and activation of the immune system. The majority of SSc patients have autoantibodies against nuclear antigens. Among these antibodies against topoisomerase I (topo I) are frequently detected in sera of SSc patients. Since the discovery of these antibodies as immunoglobulins reacting with a 70 kDa nuclear protein (Scl-70), a massive body of clinical and experimental data has been generated. In this review we summarize accumulated evidence about anti-topo I autoantibodies in SSc, including results of epitope mapping studies and investigations on the possible pathogenic role of these antibodies. (C) 2009 Elsevier B.V. All rights reserved.

引用

页码：692 / 696

页数：5

共 40 条

[1] Anti-PDGFR-α antibodies measured by non-bioactivity assays are not specific for systemic sclerosis [J].